Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan
Diabetes Research and Clinical Practice, Volume 59, No. 2, Year 2003
Notification
URL copied to clipboard!
Description
Objective: To compare insulin lispro Mix25 and human insulin 30/70 with regard to their effect on morning and evening postprandial glucose (PPG) control, and on average daily blood-glucose (BG), in patients with Type 2 diabetes who wish to fast during Ramadan. Method: Insulin lispro Mix25 and human insulin 30/70 were compared in an open-label, multicenter, randomised, crossover study involving 151 patients. Each treatment period had a duration of 14 days during which the patients self-monitored their BG before and 2 h after the main meals on any 3 days within the last 5 days of each treatment period. Results: The 2 h PPG excursion following the main evening meal after sunset was significantly lower with insulin lispro Mix25 (3.4±2.9 mmol/l) compared with human insulin 30/70 (4.0±3.2 mmol/l, P=0.007). The evening pre-meal fasting BG values were also lower with insulin lispro Mix25 (7.1±2.2 mmol/l) versus human insulin 30/70 (7.5±2.6 mmol/l, P=0.034). The average daily BG concentration was 9.5±2.4 mmol/l during treatment with insulin lispro Mix25 versus 10.1±2.5 mmol/l with human insulin 30/70 given in identical doses (P=0.004). Conclusion: When compared with human insulin 30/70, treatment of insulin-requiring Type 2 patients with insulin lispro Mix25 during Ramadan resulted in better average daily glycaemia, and better BG control before and after the evening meal. Insulin lispro Mix25 should be considered as a therapeutic option during Ramadan. © 2002 Elsevier Science Ireland Ltd. All rights reserved.
Authors & Co-Authors
Mattoo, V.
United States, Indianapolis
Eli Lilly and Company
Miličević, Zvonko
United States, Indianapolis
Eli Lilly and Company
Malone, J. K.
United States, Indianapolis
Eli Lilly and Company
Schwarzenhofer, M.
United States, Indianapolis
Eli Lilly and Company
Ekangaki, A.
United States, Indianapolis
Eli Lilly and Company
Levitt, L. K.
United States, Indianapolis
Eli Lilly and Company
Liong, L. H.C.
United States, Indianapolis
Eli Lilly and Company
Rais, Nadeem M.
India, Mumbai
Chowpatty Medical Center
Tounsi, H.
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
El Damassy, Hussien
Egypt, Cairo
Ain Shams University
Maboud, Mohamed Abdel
Egypt, Cairo
Ain Shams University
Magd, Megahed Aboul
Egypt, Mansoura
Mansoura University
Rashwan, Abdel Raouf
Egypt, Zagazig
Zagazig University
Malbari, Aqeel H.
India, Mumbai
Chowpatty Medical Center
Patel, Mahendra H.
India, Mumbai
Chowpatty Medical Center
Patel, Hasnain L.
India, Mumbai
Habib Hospital
Patel, Altaf L.
India, Mumbai
J. J. Hospital
Ahmad, Jamal
India, Aligarh
Jawaharlal Nehru Medical College
Koppad, Anand
India, Aligarh
Jawaharlal Nehru Medical College
Shukla, Nidhi
India, Aligarh
Jawaharlal Nehru Medical College
Pendek, Rokiah
Malaysia, Kuala Lumpur
Kuala Lumpur Hospital
Ooi, Cheong Guan
Malaysia, Kuala Lumpur
Kuala Lumpur Hospital
Abu Kassim, Zainab
Malaysia, Kuala Lumpur
Kuala Lumpur Hospital
Chan, Siewpheng Pheng
Malaysia, Kuala Lumpur
Kuala Lumpur Hospital
Hew, Fen Lee
Malaysia, Kuala Lumpur
Kuala Lumpur Hospital
Ismail, Ikram Shah
Malaysia, Kuala Lumpur
Kuala Lumpur Hospital
Mohamed, Mafauzy
Malaysia, Kubang Kerian
Universiti Sains Malaysia, Health Campus
Bebakar, Wan Mohamad Wan
Malaysia, Kubang Kerian
Universiti Sains Malaysia, Health Campus
Mumtaz, Malik
Malaysia, Kubang Kerian
Universiti Sains Malaysia, Health Campus
Ababou, M. R.
Morocco, Casablanca
Centre Hospitalier Universitaire Ibn Rochd
Akram, Javed
Pakistan, Lahore
Akram Medical Complex
Sarwar, Shahzad
Pakistan, Lahore
Akram Medical Complex
Basit, Abdul
Pakistan, Karachi
Baqai Medical University
Masood, Muhammad Qamar
Pakistan, Karachi
Baqai Medical University
Zafar Iqbal, S. M.
Pakistan, Karachi
Baqai Medical University
Jabbar, Abdul
Pakistan, Karachi
The Aga Khan University
Hussain, Fatirna
Pakistan, Karachi
The Aga Khan University
Lee, Chung Horn
Singapore, Singapore City
Changi General Hospital
Chen, Yuan Tud
Singapore, Singapore City
Changi General Hospital
Au, Shu Chuan Vanessa
Singapore, Singapore City
Changi General Hospital
Levitt, Naomi S.
South Africa, Observatory
Groote Schuur Hospital
Soule, Steven Grant
South Africa, Observatory
Groote Schuur Hospital
Saleh, Amr A.Hamid
Unknown Affiliation
Marwah, Renuka
Unknown Affiliation
Bajaj, Ritika
Unknown Affiliation
Awan, Asim
Unknown Affiliation
Gerber, Laudi
Unknown Affiliation
Toit, Petrus Lodewyk Du
Unknown Affiliation
Statistics
Citations: 89
Authors: 48
Affiliations: 16
Identifiers
Doi:
10.1016/S0168-8227(02)00202-4
ISSN:
01688227
Research Areas
Noncommunicable Diseases